Hemogenyx Pharmaceuticals plc (LSE:HEMO) has made a noteworthy expansion in the potential applications of its Chimeric Bait Receptor ("CBR") platform. Initially designed for treating viral diseases, the company has now demonstrated the platform's effectiveness in the treatment of cancers. Specifically, human macrophages equipped with a specially designed CBR showed high efficiency in eliminating cells derived from Non-Hodgkin Lymphoma ("NHL") in in vitro experiments. This breakthrough suggests the potential development of an efficient treatment for individuals facing relapsed and/or refractory stage III/IV metastasized NHL. Additionally, the adapted CBR construct shows promise in targeting solid tumors, including epithelial ovarian cancer and certain carcinomas.

Hemogenyx Pharmaceuticals has accelerated its research and development efforts using Artificial Intelligence ("AI")-based protein structure/interaction simulations and in-house synthesis of messenger RNA ("mRNA"). The incorporation of AI tools enables rapid triaging of CBR variants, selecting those with the highest likelihood of success. In-house mRNA synthesis facilitates the quick assembly of CBR constructs in a matter of days.

Furthermore, the company has reported ongoing tests of CBR against live infectious SARS-CoV-2, the virus responsible for COVID-19. Preliminary results indicate the effectiveness of human macrophage cells programmed with CBR against SARS-CoV-2 in in vitro experiments. These tests are conducted in a biological level three ("BSL-3") facility by an external team of scientists. Further work will focus on optimizing the application of CBR-programmed cells and obtaining in vivo results in live animal models.

Hemogenyx Pharmaceuticals, expressed excitement about the breakthrough, highlighting the platform's versatility in combating both cancers and viral infections. The company's team of scientists played a crucial role in achieving these advancements.

Non-Hodgkin Lymphoma (NHL), a subtype of lymphomas, develops in the lymph system and is primarily found in adults. It is the 11th most common cancer globally, with around 540,000 new cases and an estimated 260,000 deaths annually. In the U.S., NHL is expected to impact 80,550 people, resulting in 20,180 deaths in 2023 alone. The successful development of a new therapy for NHL holds the potential to significantly impact treatment and survival rates for this disease.

 

Source: accesswire.com

Report Abuse